ArticleCancer management and research2020
miR-105 Promotes the Progression and Predicts the Prognosis for Oral Squamous Cell Carcinoma (OSCC).
Article in Cancer management and research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 13 citations in OpenAlex.
- Heterogeneity of miRNAs in Salivary Gland Neoplasms: An Exploratory Pilot Study.Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2026Article
- Hsa_circ_0005050 regulated the progression of oral squamous cell carcinoma via miR-487a-3p/CHSY1 axis.Journal of dental sciences · 2023Article
- Research progress and clinical application prospects of miRNAs in oral cancer.Molecular biology reports · 2022Review
- Identification of key miRNAs and targeted genes involved in the progression of oral squamous cell carcinoma.Journal of dental sciences · 2022Article
- Review
- Integrative analysis of ceRNA network reveals functional lncRNAs associated with independent recurrent prognosis in colon adenocarcinoma.Cancer cell international · 2021Article
- Relevance of micro-RNAs and their targets as a diagnostic and prognostic marker in oral squamous cell carcinoma.Journal of oral and maxillofacial pathology : JOMFPReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundmiRNA-105 has been reported in a vast number of malignancies, including hepatocellular carcinoma and colorectal, esophageal, breast and non-small lung cancers. Still, the biological role of miR-105 remains mostly uncovered in oral squamous cell carcinoma (OSCC).
methodsmiR-105 expression in OSCC tissues and cell lines was detected by qRT-PCR. Survival analysis was performed using the Kaplan-Meier method, while the prognostic significance of miR-105 was evaluated by Cox regression analysis with a cohort of 90 OSCC patients. The effects of miR-105 on the proliferation of tumor cells were analyzed by CCK-8 assay and crystal violet staining, while cell invasion was assessed by transwell assays.
resultsOur current work indicates that miR-105 was upregulated in human OSCC tissues and cell lines. Moreover, miR-105 expression was closely associated with tumor size as well as clinical and differentiation stages. Notably, an elevated expression of miR-105 may predict some poor clinical prognosis in OSCC patients. Furthermore, miR-105 overexpression can significantly promote the proliferation and invasion of OSCC cells, whereas downregulation of miR-105 inhibits these cellular events.
conclusionThis study demonstrates that miR-105 can promote the proliferation and invasion of OSCC cells. High expression of miR-105 predicts poor prognosis for OSCC and, therefore, it may represent a prognostic biomarker and putative therapeutic target for patients affected by OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.